-
-
-
-
-
-
-
D. Boral Capital Upgrades Cero Therapeutics (CERO) to Buy
-
-
-
-
-
-
-
CERo Therapeutics (CERO) Regains Nasdaq Compliance
-
-
-
-
-
-
-
CERo Therapeutics (CERO) Receives FDA Clearance of Second Investigational New Drug Application to Initiate Phase 1 Clinical Trial of CER-1236
-
-
-
-
-
-
-
CERo Therapeutics (CERO) Announces 1:100 Reverse Share Split
-
-
-
-
-
-
-
CERo Therapeutics (CERO) Files for 44.13M Share Offering by Selling Stockholders
-
353,174 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

